Antibiotic resistance is the public-health driver behind much of the antimicrobial peptide pipeline. Carbapenem-resistant gram-negatives, MRSA, biofilm-producing organisms, and persister cells are the priority pathogens that small-molecule antibiotics are losing ground against.
Programs covered on this site include Peptilogics on prosthetic-joint biofilm, Fedora Pharmaceuticals' FPI-2119 lactivicin against gram-negatives, work on Acinetobacter baumannii (e.g., Barnards' neonatal sepsis program), and Longhorn Vaccines' DRG5-BD11 peptidoglycan platform. HMD-AMP discovery work from HLB Innovation also lands here.
Stories here cover the candidates, the WHO and CDC guideline updates that frame the policy fight, and the reimbursement obstacles that keep slowing AMP commercialization. See #amr and #antimicrobial-peptide for adjacent threads.
Researchers at the Hebrew University of Jerusalem designed melittin derivatives and ran experimental evolution tests in Staphylococcus aureus: full-length melittin and highly hydrophobic variants drew high resistance, while the truncated Mel(5-24) kept its antibacterial activity with minimal resistance and less cross-resistance to other peptides. Melittin-evolved bacteria shared mutations in pmtR, while Mel(5-24)-evolved bacteria changed only ydbT, and resistance tracked with peptide hydrophobicity and length, the Antimicrobial Agents and Chemotherapy paper reports. The work was done in lab cultures.
Researchers at Rzeszów University of Technology, with colleagues in Gdańsk, Kraków, and Ljubljana, built AMPAB5 from cobra (Naja ashei) venom factor sequences. Against Pseudomonas aeruginosa, which resists chloramphenicol (MIC 250 μg/mL), combining the two cut the MICs to 15.63 μg/mL for the antibiotic and 5.86 μg/mL for the peptide; AMPAB5 also blocked and cleared biofilms, modulated IL-1β and TNF-α release by human macrophages, and showed no hemolysis or toxicity to skin or Caco-2 cells, the Toxicology and Applied Pharmacology paper reports. The work was done in cells only, and two authors hold a patent assigned to the university.
Leeds Teaching Hospitals enrolled the first patient outside the U.S. in RETAIN (NCT07214311), a randomized, double-blind, placebo-controlled Phase 2/3 trial of zaloganan (PLG0206) in people having their infected knee implant cleaned and kept in place rather than replaced. The trial plans about 240 patients at 50 sites in the U.S., U.K., and Australia, with treatment failure within 12 months as its primary endpoint. Peptilogics says one of 13 patients had a recurrence in its open-label Phase 1b study, compared with published 12-month failure rates of 35% to 55% under standard care, a comparison across different studies.
Researchers at Anhui University and a Guangdong marine science lab designed two derivatives of the antimicrobial peptide MAP 34-B. MAP 34B-1 was more active against E. coli and the drug-resistant hospital pathogen Acinetobacter baumannii, cut bacterial viability within two hours by disrupting membranes, kept working under the salt and heat conditions tested, and caused less damage to mammalian cells and red blood cells than MAP 34B-2, the Journal of Peptide Science paper reports. The work was done in cell cultures only.
Using NMR spectroscopy, docking, and simulations, researchers reported in Communications Chemistry that the antimicrobial peptide thanatin binds beside the catalytic groove of NDM-1, an enzyme that lets bacteria destroy carbapenem antibiotics, and inhibits it by restricting a flexible loop while both zinc ions stay bound. In bacterial assays the effect partly restored carbapenem sensitivity, cutting viable cell output by 50% even with high enzyme levels. The work is lab-only.
Wayne State University School of Medicine researchers tested recombinant human thymosin beta-4, the protein that TB-500 is derived from, against a laboratory Staphylococcus aureus strain and two clinical isolates, reporting in Microbiology Spectrum. Alone it had little direct antibacterial activity even at high concentrations, but it acted synergistically with several of the four antibiotics tested (moxifloxacin, ciprofloxacin, oxacillin, vancomycin), mainly against free-floating bacteria. It did little against established biofilms, and all of the work was in lab dishes.
Princeton University chemists reported in ACS Chemical Biology on October 27, 2026 that conjugating a cell-penetrating peptide to the loop of the lasso peptides citrocin and microcin J25, which kill bacteria by blocking RNA polymerase but depend on specific transporters to get inside, gave them activity against all four Gram-negative ESKAPE pathogens. The conjugates were more potent than the parent peptides, with minimum inhibitory concentrations from high nanomolar to single micromolar, and entered E. coli through both transporter-dependent and transporter-independent routes, which the authors say could limit one path to resistance. The work is in bacterial cultures.
Researchers from the Chinese Academy of Sciences' Xinjiang Institute of Ecology and Geography and the Chinese Academy of Medical Sciences reported in ACS Omega on October 23, 2026 that NA-CATH, a cathelicidin peptide first found in the Chinese cobra, was the best of five antimicrobial peptides tested on clinical multidrug-resistant Klebsiella pneumoniae and Acinetobacter baumannii in the lab, but killed all treated wax moth larvae. Screening nearly 50,000 computer-designed variants produced NA-7, which kept antibacterial activity, improved survival of Klebsiella-infected larvae compared with the parent peptide, and caused lower acute toxicity and fewer kidney changes in mice. The work is preclinical.
Researchers at Houston Methodist Hospital and the National and Kapodistrian University of Athens reported in Frontiers in Microbiology on October 19, 2026 that CIT8, a 13-amino-acid antimicrobial peptide previously tuned by machine learning against MRSA, also kills drug-resistant Gram-negative bacteria. It inhibited 15 of 16 Acinetobacter baumannii strains at 4 µg/mL, including carbapenem-resistant clinical isolates, and at five times that dose cut about 50 million bacteria per mL to undetectable levels within 15 minutes by breaking their membranes. CIT8 and a mirror-image version also disrupted biofilms with relatively low toxicity to human cells; the work is in the lab.
Researchers at Zhejiang University of Technology in China and Egypt's National Research Centre reported in the Journal of Medicinal Chemistry on October 7, 2026 a deep-learning model, SMAMP, that reads peptides as full chemical structures, so it can handle unnatural amino acids and end-group changes that sequence-based models miss. Of 19 very short peptides designed with its help, 13 killed bacteria, and the model's predicted potency against E. coli tracked lab measurements (correlation 0.764). Two leads, HP-1 and HP-2, were strongly bactericidal with low toxicity to mammalian cells, led to less resistance than standard antibiotics in lab tests, protected wax moth larvae from infection, and helped wounds heal in mice.
Stanford researchers led by Eric Appel reported in the journal Matter, as described by phys.org on September 22, 2026, that they trained an AI model on known antimicrobial peptides and used it to screen 1.7 million candidate polyacrylamide polymers designed to mimic how those peptides kill bacteria. The team synthesized and tested 10 of the model's picks; all 10 performed well above expectations against E. coli, one was especially effective against biofilms, and the approach also worked against Staphylococcus aureus. Co-author Shoshana Williams called them among the most potent antimicrobial polymers ever reported. The polymers rip holes in bacterial membranes, a mechanism the researchers say makes resistance harder to evolve; clinical use remains a future goal.
A study in Nature Communications describes a linear antimicrobial peptide built from four D-tryptophan/D-arginine/D-lysine repeats that stays stable in the body and kills multidrug-resistant bacteria, including MRSA and Klebsiella pneumoniae. In bacterial pneumonia models, the peptide acted through membrane targeting alongside DNA binding, reactive-oxygen accumulation, and ATP depletion, showed low potential to drive resistance, and helped restore sensitivity to existing antibiotics.
A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.
A Nature Communications paper published April 15 reveals shared structural mechanisms between SbmA — an E. coli membrane transporter that imports antimicrobial peptides — and ABC transporters. Using cryo-electron microscopy, EPR spectroscopy, and molecular dynamics simulations, researchers demonstrated SbmA undergoes ABC-transporter-like conformational changes, informing strategies to design antibiotic-resistant-bacteria-penetrating peptide drugs.
A study in Nature Microbiology used a generative protein language model (ProteoGPT) to discover novel antimicrobial peptides effective against multidrug-resistant bacteria. The AI-designed peptides showed comparable or superior efficacy to clinical antibiotics in mouse infection models, with reduced resistance development and no organ damage.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.